KLOW vs GHK-Cu: What the Research Shows
KLOW and GHK-Cu side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider KLOW if…
- you want the added KPV component, but note its evidence is mouse and cell work only (no human trial found): KPV-treated mice recovered earlier and regained more body weight in DSS colitis.[24]
Consider GHK-Cu if…
- you want a randomized trial of the topical gel in diabetic foot ulcers (an older study): Median ulcer area closure was 98.5% with the GHK-copper gel versus 60.8% with vehicle (p < 0.05).[25]
- you want a small randomized skin-care trial with mixed results: patients reported better skin quality (P = .04) but blinded and objective evaluation found no group difference[12]
- you are tested in sport and want to avoid a WADA-prohibited substance: Klow is prohibited by WADA at all times (check GHK-Cu's own status separately)[2]
Spec comparison
Showing 10 of 12 fields where the two differ. PCAC vote, Jul 2026, Evidence strength are the same or both unknown.
| Field | KLOW | GHK-Cu |
|---|---|---|
| Class | Four-peptide blend | Copper tripeptide |
| Also called | — | copper peptide, copper tripeptide-1, GHK |
| Category | Healing & recovery | Skin & hair |
| FDA status | Not FDA approved · unstudied blend | Injectable off Category 2 (Apr 2026) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S0)Contains BPC-157 (named in S0) and TB-500 (S2.3). A blend is prohibited if any component is. | WADA status unclearGHK-Cu: This is not named on the 2026 list. The catch-all class S0 prohibits any drug with no approval anywhere for human use, so it would be banned if no health authority has approved it, but we have not verified that for this substance. |
| Anti-doping detection |
| None reportedanti-doping literature, as of 2 Oct 2026 |
| Half-life | BPC-157: less than 30 minIV and IM (single and repeated) (rat, beagle dog) · Frontiers in pharmacology 2022, PMID 36588717 | No published half-life foundPubMed search, 11 Oct 2026 |
| Evidence strength | Human RCT evidence, 4 of 4TB-500: Cardiovascular research 2025, PMID 41229390 | Human RCT evidence, 4 of 4Strongest: Archives of facial plastic surgery 2006, PMID 16847171 |
| Human studies we summarised | 15 human (9 randomized or controlled) of 65 summarised, across ingredients | 5 human (2 randomized or controlled) of 15 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 80 mg | 50 mg, 100 mg, 200 mg |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
KLOW and GHK-Cu together
People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 0 results, 2 Oct 2026).
One peptide with trials versus a four-peptide mix with none
In a laser-resurfacing study of GHK-Cu, computer analysis and blinded evaluators found no statistically significant difference between groups for earlier resolution of erythema.[12]
A systematic review of GHK-Cu says most randomized trials are small and were conducted on facial cosmetic creams.[27]
A systematic review of BPC-157 in orthopaedic sports medicine included 36 studies: 35 preclinical and 1 clinical.[28]
In a rat Achilles tendon study, combined BPC-157 and TB-500 treatment did not confer additional benefits compared with either agent alone.[29]
In a mouse DSS-colitis model, KPV led to earlier recovery and stronger regain of body weight.[24]
Practical and regulatory differences
FDA's safety note on injectable GHK-Cu says there are limited data in humans to inform safety-related considerations.[30]
For KPV, the same FDA page says it has not identified any human exposure data on drug products by any route.[30]
WADA's prohibited list names TB-500, one of KLOW's components, as an example of a derivative of thymosin-ß4.[2]
In a trial of topical GHK-Cu (lamin Gel) for diabetic ulcers, ulcer infections were significantly lower than with vehicle: 7% against 34% in plantar ulcers treated immediately after debridement.[25]
In a rat assay, GHK was rapidly degraded to HK, which was eliminated rapidly.[31]
Common questions
Is KLOW better than GHK-Cu alone?
The cached sources contain no study comparing the two. For GHK-Cu alone, a systematic review says most randomized trials are small and on facial cosmetic creams.[27]
What is the difference between KLOW and GHK-Cu?
GHK-Cu is a single copper-binding tripeptide. KLOW is a mix that also contains BPC-157, TB-500 and KPV. For BPC-157, a systematic review found 1 clinical study among 36.[28]
Is KLOW or GHK-Cu legal to buy?
FDA's compounding safety note says compounded injectable drugs containing GHK-Cu may pose a risk of immunogenicity because of potential aggregation and peptide-related impurities.[30]
Sources
- 1FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS.Molecules (Basel, Switzerland) · 2023PMID 37959764Accessed 2 Oct 2026
- 4Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H.Drug testing and analysis · 2017PMID 28035768Accessed 2 Oct 2026
- 5Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry.Journal of chromatography. A · 2012PMID 23084823Accessed 2 Oct 2026
- 6Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.Journal of separation science · 2016PMID 26578461Accessed 2 Oct 2026
- 7Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.Frontiers in pharmacology · 2022PMID 36588717Accessed 2 Oct 2026
- 8Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion.Cardiovascular research · 2025PMID 41229390Accessed 2 Oct 2026
- 9A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers.Journal of cellular and molecular medicine · 2021PMID 34346165Accessed 2 Oct 2026
- 10Recombinant human thymosin beta-4 (rhTβ4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis.Microbial biotechnology · 2021PMID 34318587Accessed 2 Oct 2026
- 11Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.Cornea · 2015PMID 25826322Accessed 2 Oct 2026
- 12Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin.Archives of facial plastic surgery · 2006PMID 16847171Accessed 2 Oct 2026
- 13Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2015PMID 25731775Accessed 2 Oct 2026
- 14PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) (431 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (humans[mh] OR patients[tiab] OR volunteers[tiab]) (150 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 16PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (randomized[tiab] OR clinical trial[pt] OR split-face[tiab]) (8 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 17PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (wound[tiab] OR hair[tiab] OR skin[tiab] OR wrinkle*[tiab]) (123 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 18PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 19PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (rat[tiab] OR mice[tiab] OR rats[tiab] OR animal[tiab]) (80 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 20PubMed search: ("GHK-Cu"[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (facial[tiab] OR cream[tiab] OR photodamage[tiab] OR volunteers[tiab] OR women[tiab]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 21PubMed search: ("GHK-Cu"[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (hair[tiab] OR alopecia[tiab]) (16 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 22PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (KPV[tiab] OR "Lys-Pro-Val"[tiab] OR "lysine-proline-valine"[tiab]))PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 23Drugs@FDA (openFDA) search: active ingredient "GHK-Cu"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 24Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.Inflammatory bowel diseases · 2008PMID 18092346Accessed 2 Oct 2026
- 25Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society · 1994PMID 17147644Accessed 2 Oct 2026
- 26PubMed search: ("GHK-Cu"[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (38 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 27A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials.Archives of internal medicine research · 2026PMID 42787770Accessed 2 Oct 2026
- 28Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2025PMID 40756949Accessed 2 Oct 2026
- 29Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.Joint diseases and related surgery · 2026PMID 42542926Accessed 2 Oct 2026
- 30Official web pageOfficial web page · web page
- 31Simultaneous determination of glycyl-L-histidyl-L-lysine and its metabolite, L-histidyl-L-lysine, in rat plasma by high-performance liquid chromatography with post-column derivatization.Journal of chromatography. B, Biomedical sciences and applications · 1997PMID 9187381Accessed 2 Oct 2026
Found an error? Report a correction.